浏览全部资源
扫码关注微信
载内皮抑素壳聚糖纳米粒联合顺铂对小鼠Lewis肺癌移植瘤的治疗作用
Preparation of endostatin-loaded chitosan nanoparticles and antitumor effect of the nanoparticles combined with cisplatin in Lewis lung cancer mice
- 第三军医大学学报 2017年39卷第2期 页码：116-122
- 作者机构：
646000 四川 泸州, 西南医科大学附属医院肿瘤科
- 作者简介：
文庆莲, E-mail: wql7315@163.com Wen Qinglian, E-mail: wql7315@163.com
- 基金信息：四川省科学技术厅科研专项资金计划项目(2014-10-146)
DOI：10.16016/j.1000-5404.201608148
中图分类号： R734.2;R943;R979.1纸质出版日期：2017-1-30，
收稿日期：2016-8-25，
录用日期：2016-10-30
扫 描 看 全 文
丁瑞麟, 谢芳, 胡月, 等. 载内皮抑素壳聚糖纳米粒联合顺铂对小鼠Lewis肺癌移植瘤的治疗作用[J]. 第三军医大学学报, 2017,39(2):116-122.
Ruilin Ding, Fang Xie, Yue Hu, et al. Preparation of endostatin-loaded chitosan nanoparticles and antitumor effect of the nanoparticles combined with cisplatin in Lewis lung cancer mice[J]. J Third Mil Med Univ, 2017,39(2):116-122.
丁瑞麟, 谢芳, 胡月, 等. 载内皮抑素壳聚糖纳米粒联合顺铂对小鼠Lewis肺癌移植瘤的治疗作用[J]. 第三军医大学学报, 2017,39(2):116-122. DOI： 10.16016/j.1000-5404.201608148.
Ruilin Ding, Fang Xie, Yue Hu, et al. Preparation of endostatin-loaded chitosan nanoparticles and antitumor effect of the nanoparticles combined with cisplatin in Lewis lung cancer mice[J]. J Third Mil Med Univ, 2017,39(2):116-122. DOI： 10.16016/j.1000-5404.201608148.
摘要
目的
2
制备载内皮抑素(endostain，ES)壳聚糖纳米粒(endostatin-loaded chitosan nanoparticles，ES-NPs)，并探讨其联合顺铂(cisplatin，DDP)对小鼠Lewis肺癌模型的治疗作用。
方法
2
采用离子凝胶法制备ES-NPs，并对其形态及基本性质进行研究。建立小鼠Lewis肺癌皮下移植瘤模型，按随机数字表法分为对照组、ES组、DDP组、ES-NPs组、ES+DDP组、ES-NPs+DDP组。各组给药后，动态测量小鼠移植瘤体积，免疫组化检测移植瘤组织中微血管密度(microvessel density，MVD)，ELISA检测小鼠血清中内皮抑素和VEGF水平。
结果
2
制备的ES-NPs具有合适的粒径和较高的包封率，在体外具有明显缓释性，7 d累积释放量达(60.22±2.58)%。当ES-NPs与DDP联合时，能明显抑制肺癌移植瘤生长，观察结束时，ES-NPs+DDP组的抑瘤率为76.47%，明显高于ES+DDP组及其余各组(
P
＜0.05)。同时，免疫组化和ELISA检测结果证实了ES-NPs与DDP联合对肿瘤血管具有较强的抑制作用。
结论
2
内皮抑素纳米粒联用DDP可增强对小鼠Lewis肺癌移植瘤的抗瘤效果。
Abstract
Objective
2
To prepare endostatin-loaded chitosan nanoparticles (ES-NPs)
and investigate the antitumor effect of the nanoparticles combined with cisplatin (DDP) in Lewis Lung cancer mice.
Methods
2
ES-NPs were prepared with a simple ionic crosslinking method. The characterization of ES-NPs
including size distribution
zeta potential
loading efficiency
encapsulation efficiency and release behavior
was determined. Subcutaneous Lewis lung cancer xenograft model of C57BL/6J mice was established
and the mice were randomly divided into 6 groups: control group (0.9% NaCl)
ES group
DDP group
ES-NPs group
ES+DDP group
and ES-NPs+DDP group. After drug administration
the volume of xenograft tumor in different groups was measured dynamically. The microvascular density (MVD) in xenograft tumor tissues was detected by immunohistochemical assay. The serum vascular endothelial growth factor (VEGF) and endostatin levels were determined by enzyme-linked immunosorbent assay (ELISA).
Results
2
ES-NPs were successfully synthesized and had suitable size distribution and high encapsulation efficiency. The NPs were spherical and homogeneous in shape
and exhibited an ideal releasing profile
in vitro
. The tumor growth was significantly inhibited after treatment with ES-NPs combined with DDP. The tumor inhibitory rate was much higher in the ES-NPs+DDP group than in the other groups (
P
＜0.05). Moreover
the results of immunohistochemical assay and ELISA confirmed that ES-NPs combined with DDP had strong effect on inhibiting tumor angiogenesis.
Conclusion
2
ES-NPs can overcome the shortcomings of free ES
such as short retention time in circulation
and can enhance antitumor efficacy of ES. When the nanoparticles are combined with DDP
the antitumor effect becomes stronger.
关键词
肺肿瘤内皮抑素纳米粒壳聚糖顺铂
Keywords
lung cancerendostatinnanoparticleschitosancisplatin
references
O'Reilly M S, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 88(2): 277-285. DOI: 10.1016/S0092-8674(00)81848-6
Wei Z, Yang C, Song X, et al.Endostatin specifically targets both tumor blood vessels and lymphatic vessels[J]. Front Med, 2011, 5(4): 336-340.DOI: 10.1007/s11684-011-0163-5
Han B, Xiu Q, Wang H, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer[J]. J Thoracic Oncol, 2011, 6(6): 1104-1109. DOI: 10.1097/JTO.0b013e3182166b6b
Sun X J, Deng Q H, Yu X M, et al. A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer[J]. BMC Cancer, 2016, 16(1): 266. DOI: 10.1186/s12885-016-2234-0
Shi Y, Sun Y. Medical management of lung cancer: Experience in China[J]. Thorac Cancer, 2015, 6(1): 10-16. DOI: 10.1111/1759-7714.12168
Wang J J, Zeng Z W, Xiao R Z, et al.Recent advances of chitosan nanoparticles as drug carriers[J]. Int J Nanomedicine, 2011, 6: 765-774.DOI: 10.2147/IJN.S17296
许向阳, 李玲, 王青松, 等. 重组人血管内皮抑素壳聚糖纳米粒的制备及体外评价[J]. 中国药科大学学报, 2011, 42(1): 44-47. DOI: 10.11665/j.issn.1000-5048.20110108
Rampino A, Borgogna M, Blasi P, et al.Chitosan nanoparticles: preparation, size evolution and stability[J]. Int J Pharm, 2013, 455(1/2): 219-228. DOI: 10.1016/j.ijpharm.2013.07.034
Hu S, Zhang Y. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation[J]. Int J Nanomedicine, 2010, 5: 1039-1048. DOI: 10.2147/IJN.S14753
Du Y, Zhang Q, Jing L, et al. GX1-conjugated poly(lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment[J]. Int J Nanomedicine, 2015, 10: 3791-3802. DOI: 10.2147/IJN.S82029
李萌, 丁瑞麟, 文庆莲. 重组人血管内皮抑素联合紫杉醇不同时序给药降低肺癌移植瘤小鼠血清中VEGF和HIF-1α的水平及其意义[J]. 肿瘤, 2016, 36(3): 264-271. DOI: 10.3781/j.issn.1000-7431.2016.11.914
Fan J, Du J, Wu J, et al. Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma[J]. Oncol Lett, 2015, 9(2): 822-828.DOI: 10.3892/ol.2014.2783
Weidner N, Semple J P, Welch W R, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma[J]. N Engl J Med, 1991, 324(1): 1-8. DOI: 10.1056/nejm199101033240101
Xu X, Mao W, Chen Q, et al. Endostar, a Modified Recombinant Human Endostatin, Suppresses Angiogenesis through Inhibition of Wnt/beta -Catenin Signaling Pathway[J]. PLoS One, 2014, 9(9): e107463. DOI: 10.1371/journal.pone.0107463
Fu X H, Li J, Zou Y, et al. Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft[J]. Cancer Lett, 2011, 312(1): 109-116. DOI: 10.1016/j.canlet.2011.08.008
Ling Y, Yang Y, Lu Y, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells[J]. Biochem Biophys Res Commun, 2007, 361(1): 79-84. DOI: 10.1016/j.bbrc.2007.06.155
金一, 余传信. 蛋白质及多肽类药物长效化研究进展[J]. 中国血吸虫病防治杂志, 2012, 24(5): 594-597. DOI: 10.3969/j.issn.1005-6661.2012.05.027
Tong Y, Zhong K, Tian H, et al. Characterization of a monoPEG20000-Endostar[J]. Int J Biol Macromol, 2010, 46(3): 331-336. DOI: 10.1016/j.ijbiomac.2010.01.017
Wu J, Wu L, Xu X, et al. Microspheres made by w/o/o emulsion method with reduced initial burst for long-term delivery of endostar, a novel recombinant human endostatin[J]. J Pharma Sci, 2009, 98(6): 2051-2058. DOI: 10.1002/jps.21589
罗小林, 易丹丹. 抗肿瘤药物纳米给药系统研究进展[J]. 医药导报, 2015, 34(2): 218-222. DOI: 10.3870/yydb.2015.02.022
Amidi M, Mastrobattista E, Jiskoot W, et al. Chitosan-based delivery systems for protein therapeutics and antigens[J]. Adv Drug Deliv Rev, 2010, 62(1): 59-82.DOI: 10.1016/j.addr.2009.11.009
Agnihotri S A, Mallikarjuna N N, Aminabhavi T M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery[J]. J Control Release, 2004, 100(1): 5-28.DOI: 10.1016/j.jconrel.2004.08.010
Dong X P, Xiao T H, Dong H, et al. Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice[J]. Asian Pac J Cancer Prev, 2013, 14(5): 3079-3083.
Yu Z W, Ju Y H, Yang C L, et al. Antitumor effect of recombinant human endostatin combined with cisplatin on rats with transplanted Lewis lung cancer[J]. Asian Pac J Trop Med, 2015, 8(8): 664-667. DOI: 10.1016/j.apjtm.2015.07.010
Sun J, Deng L, Duan Y, et al. Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice[J]. Exp Ther Med, 2012, 3(2): 159-164. DOI: 10.3892/etm.2011.384
Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Exp Cell Res, 2006, 312(5): 594-607. DOI: 10.1016/j.yexcr.2005.11.015
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
